###### Strengths and limitations of this study

-   This is the first study to investigate the feasibility and acceptability of a therapist-guided, internet-based cognitive--behavioural therapy intervention, delivered from a single centre, to an international sample with global eligibility for inclusion.

-   The absence of a control condition limits the ability to make inferences about what caused the changes observed.

-   Since most participants resided in Western countries, it is unclear to what extent body dysmorphic disorder-NET is generalisable to patients from non-Western cultures.

Introduction {#s1}
============

Despite the enormous socioeconomic costs and individual suffering caused by mental illness, there are far too few clinicians to meet the global need for mental health services.[@R1] Moreover, outpatient health services are usually open during normal working hours, and this current service model disenfranchises individuals who may have difficulties taking time off work or accessing care if living in remote and underserved areas. Furthermore, issues like stigma, lack of awareness, cost of treatment, and the symptoms of psychiatric disorders themselves can also be barriers to accessing care.[@R3] As a result, most individuals with a mental disorder do not receive treatment.[@R4]

This treatment gap is particularly wide for under-recognised disorders such as body dysmorphic disorder (BDD), where the affected individual is preoccupied with perceived flaws or defects in one's appearance that are not noticeable to others.[@R5] In fact, only 10%--17% of those with the disorder report receiving an evidence-based psychotherapy like cognitive--behavioural therapy (CBT), despite its common prevalence and significant functional impairment for sufferers.[@R3]

Internet-based CBT (ICBT) aims to increase accessibility and availability to specialised treatment and has been shown to be efficacious and cost-effective for a range of disorders.[@R11] While ICBT has been studied for nearly 20 years,[@R12] there has been an upsurge of promising research on technology-based mental health interventions during the past several years.[@R13] Recently, BDD-NET, a therapist-guided, ICBT programme for BDD, was developed to improve access to evidence-based care, and the treatment has been shown to be safe, efficacious and highly acceptable by patients.[@R15] The treatment is delivered through a secure tailored online platform that contains the treatment content. Communication between therapist and patient is done through asynchronous messaging, requiring only a fraction of therapist time compared with conventional CBT. Crucially, BDD-NET removes key barriers to treatment, while yielding outcomes equivalent to traditional face-to-face CBT.[@R17]

ICBT represents a promising solution for economically and efficiently targeting mental health disparities around the world. However, this integration of CBT with information technology has yet to realise its true potential to reach underserved populations. Therefore, our aim was to conduct the first investigation evaluating whether a therapist-guided, ICBT intervention could be delivered safely and effectively across international borders, with no geographical restrictions for recruitment. In doing so, the current researchers hope to shed light on aspects of feasibility and ethical considerations that arise in this novel treatment context.

Methods {#s2}
=======

Trial design {#s2a}
------------

The aim of this investigation was to evaluate the feasibility and safety of a global treatment initiative using an English-language version of BDD-NET.[@R15] This uncontrolled pilot study was intended to assess different aspects of conducting the study remotely and across international borders; including recruitment, assessment and treatment delivery.

Procedure {#s2b}
---------

Participants were recruited by clinician referral as well as using internet advertisements through Google AdWords, bddfoundation.org and on internet forums. Individuals interested in participating in the study were directed to the study's website where they provided initial informed consent, and completed an online screening consisting of the Montgomery-Åsberg Depression Rating Scale, Self-Report (MADRS-S),[@R18] the Body Dysmorphic Disorder Questionnaire (BDDQ),[@R20] the Dysmorphic Concerns Questionnaire (DCQ),[@R21] the Alcohol Use Disorders Identification Test (AUDIT),[@R22] and the Drug Use Disorders Identification Test (DUDIT).[@R23] Following this initial screening, eligible individuals were invited for an assessment over VSee, a Health Insurance Portability and Accountability Act (HIPAA) compliant video-conferencing software. During the video-conference assessment, final screening and baseline measures were obtained, as well as verbal informed consent, identification documents and emergency information. Measures administered at this time were the BDD modification of the Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS),[@R24] Columbia Suicide Severity Rating Scale (C-SSRS),[@R25] Brown Assessment of Beliefs Scale (BABS),[@R26] Clinical Global Impressions Scale of Severity (CGI-S)[@R27] and Global Assessment of Functioning (GAF).[@R5] Additionally, the obsessive--compulsive and related disorders module of the Structured Clinical Interview for DSM-5[@R28] and the Mini-International Neuropsychiatric Interview 7[@R29] were also administered at this time as a means to establish a primary diagnosis of BDD. For full eligibility criteria and details on recruitment and patient flow, see online [supplementary appendix A](#SP1){ref-type="supplementary-material"}. Eligible participants were then granted access to treatment via the online platform. In order to guarantee participant confidentiality, we used a dedicated server with encrypted traffic and a strong authentication login function.
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Participants {#s2c}
------------

Thirty-two participants were included in the study. These individuals resided in 9 different countries and represented 12 different nationalities (sociodemographic and clinical characteristics of participants are presented in [table 1](#T1){ref-type="table"}). Inclusion criteria were that participants needed to be aged 18 years or older, meet DSM-5 criteria for a diagnosis of BDD with symptom severity measuring ≥20 on the BDD-YBOCS,[@R24] be outpatient, be fluent in English and have regular access to a computer with an internet connection. Patients who were able to navigate the online registration and screening process were considered to have sufficient computer skills to participate in the study.

###### 

Sociodemographic and clinical characteristics of the sample (N=32)

  Variable                                       
  ---------------------------------------------- --------------
  Gender, n (%)                                  
   Men                                           8 (25)
   Women                                         24 (75)
  Age, mean (SD)                                 31.91 (7.44)
  Highest education, n (%)                       
   Primary school                                1 (3.1)
   High school                                   6 (18.8)
   Bachelor's degree                             14 (43.8)
   Master's degree                               10 (31.2)
   Doctorate degree                              1 (3.1)
  Occupational status, n (%)                     
   Working, full time                            9 (28.1)
   Working, part time                            10 (31.2)
   Student                                       7 (21.9)
   Unemployed                                    5 (15.6)
   Disability pension                            1 (3.1)
  Years with BDD, mean (SD)                      16.22 (9.10)
  No of areas of concern, mean (SD)              12.16 (5.84)
  Comorbid conditions, n (%)                     
   Major depressive disorder                     10 (31.2)
   Panic disorder                                2 (6.2)
   Social anxiety disorder                       5 (15.6)
   Generalised anxiety disorder                  5 (15.6)
  Current medication, n (%)                      
   SSRI                                          2 (6.2)
   SNRI                                          3 (9.4)
   Benzodiazepines                               1 (3.1)
   Stimulants                                    1 (3.1)
  Previous psychological treatment, n (%)        25 (78.1)
   CBT                                           8 (32.0)
   PDT                                           2 (8.0)
   Non-specific counselling                      12 (48.0)
   Religious counselling                         1 (4.0)
   Unknown                                       2 (8.0)
  Plastic surgery                                
   Previous plastic surgery, n (%)               13 (40.6)
   No of surgeries, mean (SD)                    1.38 (2.46)
  Nationality, n (%)                             
   American                                      12 (37.5)
   Swedish                                       7 (21.9)
   Indian                                        1 (3.1)
   Bulgarian                                     1 (3.1)
   Finnish                                       1 (3.1)
   English                                       4 (12.5)
   Serbian                                       1 (3.1)
   South Korean                                  1 (3.1)
   Irish                                         1 (3.1)
   Norwegian                                     1 (3.1)
   Sri Lankan                                    1 (3.1)
   Lithuanian                                    1 (3.1)
  Dysmorphic Concerns Questionnaire, mean (SD)   15.63 (2.50)

BDD, body dysmorphic disorder; CBT, cognitive--behavioural therapy; PDT, psychodynamic therapy; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

Exclusion criteria were concurrent psychological treatment, having received CBT for BDD within 12 months preceding treatment, changes in psychotropic medications within 12 weeks before inclusion, not having access to a 24-hour psychiatric emergency centre in their proximity, or if they could not provide an emergency contact person. Additional grounds for exclusion were current substance dependence, lifetime bipolar disorder or psychosis, MADRS-S score ≥35, personality disorder diagnosis, lifetime history of suicide attempts or clinically significant current suicidal ideation (≥5 on item 9 of MADRS-S; C-SSRS (past month)---Most Severe Ideation score ≥4). Patients excluded from the study prior to enrolment due to excessive depression or suicidality were subjected to the same safety procedures as patients who were included. They agreed to go to an identified, local 24 hours psychiatric emergency centre in the event that they were at imminent risk and were referred to mental health services in their area for ongoing care.

Patient and public involvement {#s2d}
------------------------------

Patients and the general public did not have direct involvement in the design of this study, recruitment or the development of research questions or measures. On publication, patients will be sent a copy of the article which would not have been possible without their participation.

Primary outcome {#s2e}
---------------

The primary outcome was the BDD-YBOCS, administered at baseline, mid-treatment (week 6), post-treatment (week 12) and 3 months after treatment completion. BDD-YBOCS is a semistructured clinician-administered scale, considered to be the gold standard for measuring BDD symptom severity and has demonstrated good psychometric properties.[@R30] Scores range from 0 to 48 with higher scores indicating greater severity. Prior to subject enrolment, all evaluators were trained to a reliability criterion (intraclass correlation coefficient of at least. 85) with a gold-standard rater on the BDD-YBOCS.

Secondary outcomes {#s2f}
------------------

Participants with ≥30% reduction on the BDD-YBOCS were considered responders.[@R30] Participants no longer meeting full criteria for DSM-5 diagnostic criteria for BDD were considered to be in remission.

Clinicians rated patient overall severity and symptom change on the CGI. The CGI-S ranges from 1 (normal, not ill at all) to 7 (among the most extremely ill of subjects). Similarly, the CGI-I ranges from 1 (very much improved) to 7 (very much worse).[@R27] Secondary measures of symptoms included the MADRS-S,[@R18] GAF[@R5] and BABS.[@R26] See online [supplementary appendix A](#SP1){ref-type="supplementary-material"} for a complete list of secondary outcome measures.

Treatment activity, completion and acceptability {#s2g}
------------------------------------------------

Therapist time spent on the platform reviewing patient progress and responding to messages, the number of messages sent and received, and the number of completed modules were automatically recorded for each patient. Patients rated working alliance every 2 weeks throughout treatment using the Working Alliance Inventory\--Short Revised (WAI-SR).[@R31] At post-treatment, patients rated treatment satisfaction on the client satisfaction inventory (CSI).[@R32] Patient credibility and expectancy were also recorded every 2 weeks throughout treatment using the Credibility/Expectancy Questionnaire (CEQ).[@R33]

Adverse events monitoring {#s2h}
-------------------------

Each week patients were asked if they experienced any adverse events or side effects that could be attributed to treatment (eg, sleep disturbances, increased anxiety or depression symptoms). If so, they were asked to describe them in the form of free text.[@R35]

For a full list of outcome measures used, as well as a detailed timetable for their administration, see protocol in online [supplementary appendix A](#SP1){ref-type="supplementary-material"}.

Intervention {#s2i}
------------

BDD-NET, a 12-week internet-delivered CBT intervention for BDD, was evaluated in Sweden in a pilot study (n=23) and then in a randomised controlled trial (n=94), and showed sustained effects at 2-year follow-up.[@R15] It was translated to English for the current study in order to reach an international sample (For a full description of the treatment content, see refs[@R15]). Throughout treatment, patients had unlimited access to their therapist from Monday to Friday via asynchronous electronic text messages. The therapist's primary role was to offer clarification and emotional support, and to help participants design and practice exposure and response prevention (EX/RP) exercises that targeted their treatment goals. They also reminded participants to complete treatment content in time via text message reminders. Therapists were doctoral-level psychology students with no previous experience treating BDD, and were supervised by licensed psychologists and psychiatrists based at Karolinska Institutet. Similar to the delivery of the treatment itself, supervision was primarily delivered at least once per week, on a continuous basis, any time that decisions were made related to patient inclusion/exclusion or withdrawal from treatment, any time a patient reported elevated risk, and as needed to address other questions related to the delivery of the treatment itself.

Safety procedures {#s2j}
-----------------

Before the start of treatment, researchers verified the 24 hours emergency psychiatric centres in each participant's local area. Symptom levels and adverse events were evaluated weekly via the platform and considered along with patients' message content in order to continuously assess risk. Any increase in suicidal ideation (eg, MADRS-S item 9≥4) was automatically flagged by the system and prompted the therapist for further assessment (see online [supplementary appendix A](#SP1){ref-type="supplementary-material"} for details on this procedure).

Statistical analyses {#s2k}
--------------------

All statistical analyses are reported according to 'intention-to-treat' principles unless otherwise stated. Linear mixed models were used to assess continuous outcomes, with time as a fixed effect and random intercepts for each participant,[@R37] and reported using maximum likelihood estimation with 95% CIs around estimated means. We calculated Cohen's *d* by dividing the estimated change by the SD of that measure at pretreatment. For non-continuous outcomes, ordinal logistic regression was used with a fixed effect of time, reported as proportional ORs with 95% CIs. To examine whether data could be deemed to be missing at random, we compared completers (ie, those with BDD-YBOCS data at follow-up) with non-completers on baseline measurements from [table 1](#T1){ref-type="table"}, using t-tests or χ^2^ tests where appropriate. Analyses were performed in R (V.3.4.4) and in SPSS V.25.

Results {#s3}
=======

In total, 32 participants initiated treatment, 25 participants (78%) completed mid-treatment assessments, 21 (66%) post-treatment and 25 participants (78%) follow-up assessments, respectively (see [figure 1](#F1){ref-type="fig"} for patient flow throughout the study). There were no statistically significant differences between completers and non-completers on baseline demographic and clinical variables (p=0.29--0.91), except that non-completers, on average, had undergone more previous plastic surgeries (p=0.03).

![Participant flow through the study. BDD-YBOCS, Body Dysmorphic Disorder modification of the Yale-Brown Obsessive Compulsive Scale.](bmjopen-2018-024693f01){#F1}

Primary outcome {#s3a}
---------------

From baseline to week 6, participants made significant improvements on the BDD-YBOCS (estimate −8.12, 95% CI −10.93 to −5.32, d=1.66, p\<0.001). Further improvements were seen at post-treatment (estimate −12.63, 95% CI −15.61 to −9.65, d=2.57, p\<0.001) and were maintained at the 3-month follow-up (estimate −11.71, 95% CI −14.52 to −8.91, d=2.39, p\<0.001). The effect of time in a linear mixed effects model was significant (F(3, 71.63)=31.79, p\<0.001). These outcomes were similar to those of the previous BDD-NET trials (see [figure 2](#F2){ref-type="fig"}).

![Clinician-rated BDD-YBOCS, comparison with previous BDD-NET trials. BDD-YBOCS, Body Dysmorphic Disorder modification of the Yale-Brown Obsessive Compulsive Scale.](bmjopen-2018-024693f02){#F2}

Secondary outcomes {#s3b}
------------------

At post-treatment, 15 participants (47%, 95% CI 24% to 70%) were considered treatment responders, with 16 (50%, 95% CI 29% to 71%) participants considered responders at 3-month follow-up. At post-treatment, 9 participants (28%, 95% CI 7% to 49%) no longer met criteria for BDD, which increased to 14 (44%, 95% CI 23% to 65%) at the 3-month follow-up.

Participants showed statistically significant improvements on the CGI-S at post-treatment (proportional OR, pOR 0.17, 95% CI 0.06 to 0.47, p\<0.001) and at 3-month follow-up (pOR 0.22, 95% CI 0.07 to 0.60, p=0.004). The majority of participants who participated in post-treatment and follow-up assessments were much improved or very much improved on the CGI-I after treatment (see [figure 3](#F3){ref-type="fig"}).

![CGI improvement. CGI, Clinical Global Impressions Scale.](bmjopen-2018-024693f03){#F3}

Additionally, participants showed significant improvement in depressive symptoms measured using the MADRS-S (F(13, 243.83)=5.85, p\<0.001), global functioning using the GAF (F(2, 46.89)=10.46, p\<0.001) and insight using the BABS (F(2, 47.36)=10.11, p\<0.001). See [table 2](#T2){ref-type="table"} for estimated means and change on primary and secondary outcome measures.

###### 

Estimated means and change on primary and secondary outcomes

  ------------------------------------------------------------------------------------------
  Outcome     Time        Estimated mean (SE)   Estimated change\          d       P value
                                                (95% CI)                           
  ----------- ----------- --------------------- -------------------------- ------- ---------
  BDD-YBOCS   Pre         28.72 (1.35)                                             

              Mid         20.6 (1.43)           −8.12 (−10.93 to −5.32)    −1.66   0.001

              Post        16.09 (1.52)          −12.63 (−15.61 to −9.65)   −2.57   0.001

              Follow-up   17.01 (1.43)          −11.71 (−14.52 to −8.91)   −2.39   0.001

  MADRS-S     Pre         20.16 (1.59)                                             

              Week 1      19.54 (1.08)          −0.62 (−2.74 to 1.51)      −0.07   0.57

              Week 2      17.02 (1.09)          −3.14 (−5.28 to −1)        −0.38   0.004

              Week 3      17.24 (1.11)          −2.91 (−5.1 to −0.73)      −0.35   0.01

              Week 4      16.15 (1.16)          −4.01 (−6.29 to −1.72)     −0.48   0.001

              Week 5      16.8 (1.13)           −3.35 (−5.57 to −1.14)     −0.4    0.003

              Week 6      16.7 (1.23)           −3.46 (−5.86 to −1.06)     −0.42   0.005

              Week 7      14.76 (1.25)          −5.4 (−7.84 to −2.95)      −0.65   0.001

              Week 8      15.37 (1.28)          −4.78 (−7.29 to −2.28)     −0.58   0.001

              Week 9      14.88 (1.25)          −5.27 (−7.72 to −2.82)     −0.63   0.001

              Week 10     16.37 (1.21)          −3.78 (−6.14 to −1.42)     −0.46   0.002

              Week 11     13.5 (1.34)           −6.66 (−9.28 to −4.03)     −0.8    0.001

              Post        13.36 (1.17)          −6.8 (−9.08 to −4.51)      −0.82   0.001

              Follow-up   12.37 (1.3)           −7.78 (−10.34 to −5.23)    −0.94   0.001

  BABS        Pre         14.75 (1.06)                                             

              Post        10.1 (1.18)           −4.65 (−6.96 to −2.34)     −0.98   0.001

              Follow-up   10.72 (1.1)           −4.03 (−6.19 to −1.87)     −0.85   0.001

  GAF         Pre         57.34 (1.73)                                             

              Post        67.43 (2.2)           10.08 (5.76 to 14.4)       0.94    0.001

              Follow-up   61.55 (2.07)          4.21 (0.15 to 8.27)        0.39    0.048
  ------------------------------------------------------------------------------------------

P values: estimated change.

BABS, Brown Assessment of Beliefs Scale; BDD-YBOCS, Body Dysmorphic Disorder modification of the Yale-Brown Obsessive Compulsive Scale; d, Cohen's d; GAF, Global Assessment of Functioning; MADRS-S, Montgomery-Åsberg Depression Rating Scale--Self-Rated.

Treatment activity, completion and acceptability {#s3c}
------------------------------------------------

Therapists spent an average of 15.2 min supporting patients (SD=12.1 min) per participant per week, and sent or received an average of 3.7 (SD=2.7) messages per week. For each additional message sent, participants had, on average, a reduction of of 0.11 points on the BDD-YBOCS (95% CI −0.23 to 0.01), but the number of messages sent was not a statistically significant predictor of BDD-YBOCS score when controlling for time (F\[1, 28.80\]=3.01, p=0.09). In total, 18 (56%) participants completed the core treatment content (modules 1--5). Eight participants (25%) completed all eight modules. The mean number of modules completed was 5.1 (SD=2.47). Individuals who completed at least five modules had, on average, a lower score on the BDD-YBOCS over time (estimate −6.35, 95% CI −11.72 to −0.99). The effect of number of modules completed was statistically significant when including time as a covariate (F\[1, 37.62\]=5.39, p=0.03). The following results on acceptability measures reflect patient responses at post-treatment which could not be acquired from the entire sample, and therefore, are not intention-to-treat analyses. The mean WAI-SR score after treatment was 49.7 (SD=10.7) out of a possible 60, indicating a strong therapeutic bond. Additionally, 95% of participants who gave feedback at post-treatment (20/21) reported that they felt well supported or very well supported by their therapist. Furthermore, despite the fact that some participants were not native English speakers, 95% of participants found the language used in treatment to be easy or very easy to understand. On average, participants were satisfied with the treatment and found it to be credible. Treatment satisfaction on the CSI was moderate to high at post-treatment, with a mean score of 129.4 (SD=32.6) out of a possible 175. Participants rated treatment credibility as moderate on the CEQ at post-treatment (mean=33.1, SD=9.8).

Adverse events {#s3d}
--------------

During the course of treatment, (8/32) 25% of participants reported at least one mild adverse event, which did not pose any acute health risk. This included increased depressive symptoms (21.9%), a temporary increase in anxiety (15.6%), sleep disturbance or nightmares (9.4%) and feelings of shame (6.3%). Two adverse events needed further action due to increased suicidal ideation. One participant was admitted to high-intensive psychiatric care and ended participation in the study. In this case, researchers facilitated the connection to services in the participant's local area. Another participant who reported a high frequency of suicidal ideation remained in the study and was monitored by a local psychiatrist who had previously treated the patient.

Discussion {#s4}
==========

Here, we report the results of the first fully remote, psychological treatment, of BDD or any other disorder, without any geographical restrictions for enrolment. We found that BDD-NET was associated with a large reduction of BDD symptoms at post-treatment and follow-up. Participant-rated reductions in body dysmorphic symptoms and depressive symptoms were 46% and 34%, respectively. Remission rates were 28% at post-treatment and 44% at follow-up. Additionally, patients at post-treatment (n=21) reported a strong therapeutic bond with mean WAI-SR scores at 49.8 (SD=10.4) out of a possible 60. The safety procedures tested in this study worked well. These results indicate that delivering BDD-NET across international borders is feasible, safe and acceptable to clients. Furthermore, as required therapist time was minimal as compared with face-to-face CBT, our findings highlight international ICBT treatment as a promising solution to the global mental health epidemic.

Comparison to previous results {#s4a}
------------------------------

Current results are in line with previous evaluations of BDD-NET as well as face-to-face CBT for BDD.[@R15] These findings suggest that delivering BDD-NET across borders in a new language, to a more culturally diverse patient population, had little to no impact on treatment effects. That said, these data are not sufficient to conclude that the treatment effects are universally generalisable. While our sample comprises 12 different nationalities, only 25% came from non-Western cultures. Post hoc analyses did not identify nationality as a statistically significant predictor of BDD-YBOCS score, but larger samples recruiting more heavily from non-Western countries are needed to detect differences between nationalities and to determine if adaptations should be made to the core treatment content.

Limitations {#s4b}
-----------

While the amount of missing data (35% at post-treatment and 21% at follow-up) is higher than previous investigations of BDD-NET (4% at post-treatment and 9% at follow-up in BDD-NET pilot), it is similar to estimates from recent meta-analyses of both face-to-face and internet CBT.[@R38] Furthermore, our sensitivity analysis showed that participants with incomplete data at post-treatment did not differ from participants with complete post-treatment data on most baseline measures. However, participants with missing data did report more cosmetic surgeries. This could potentially be related to poorer insight or higher overall severity, which in turn could have impacted their commitment to treatment. Also, since there was no active comparison group, one cannot conclusively say that treatment caused the improvements that were observed. However, this was not the primary aim of the current study since the specific treatment effects of BDD-NET have already been established in comparison with online supportive therapy.[@R16]

Challenges for clinical trials with global inclusion {#s4c}
----------------------------------------------------

### Legal considerations {#s4c1}

Trials are currently regulated by ethical review boards at universities and healthcare providers. These typically oversee research at their specific site. While multicentre trials may be international, this is to our knowledge the first one-site therapist-guided ICBT treatment study with global eligibility for inclusion. Legislation on ethical vetting is by default national and there are presently no clear guidelines on how trials with international participation of study subjects should be regulated. Internet treatment may also be subject to regulations that govern communications as well as clinical practice. Any legal ambiguity could potentially put some patients at risk when receiving treatment. Therefore, it is essential that international treatment programmes protect patients' privacy and safety in this new context.

### Risk management {#s4c2}

Another challenge for studies with global eligibility for inclusion is to ensure adequate care for at-risk patients while also reaching those in need of treatment. While high-risk patients may make clinicians uncomfortable due to liability concerns, many patients seek out ICBT because it is their only viable treatment option. Our procedure for monitoring and responding to suicidality was effective in ensuring patient safety despite the distance between patients and clinicians. One strategy used in this study to manage higher risk patients was to partner with local mental health practitioners who could facilitate risk assessment and expedite a safety plan in their local area if necessary. Psychiatrists can function particularly well in this role, as pharmacological treatment (when indicated) could complement ICBT treatment with minimal redundancy or interference. It is our view that offering remotely delivered evidence-based treatment will always be safer for patients than not having access to treatment at all.

### Cultural differences {#s4c3}

International ICBT treatment also poses some novel challenges to cultural competence. Patients not only have different cultural backgrounds, but are currently residing in a different cultural context. Therefore, cultural considerations in treatment may be magnified. Special care should be taken when establishing treatment goals and designing exposure exercises that are culturally appropriate. While our results suggest that a competent therapist can adapt the treatment to the needs of patients from different cultural backgrounds, it should be noted that the participants in this trial were relatively homogeneous (mainly from industrialised nations, highly educated, good command of English language, availability of local psychiatric services). Therefore, it is not yet clear to what extent ICBT can be made available in other settings. Furthermore, while the assessment instruments used in the current study are the most widely used and accepted among BDD researchers, they were developed and validated within Western cultures, with primarily native English speakers. Therefore, it is not yet clear to what extent these instruments assess the same psychological constructs for participants from non-Western backgrounds.

Conclusion {#s5}
==========

This is, to our knowledge, the first investigation of a fully remote, therapist-guided psychological treatment with recruitment efforts deployed on a global scale. We found large reductions in core BDD symptomatology, with 44% of patients in remission at follow-up. Participants accepted the treatment and rated their therapist as supportive in the majority of cases. Future trials should evaluate the specific effects of BDD-NET compared with a credible control condition and strive to include more participants from non-Western cultures. In summary, we found that an internet-delivered treatment for BDD can be delivered fully remotely with intact treatment effects, and in a safe way, across countries.
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